

ANTIGENICS INC /DE/  
Form SC 13G/A  
June 13, 2005

OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden hours per response...11

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 2)\*

ANTIGENICS INC.

---

(Name of Issuer)

COMMON STOCK, \$0.01 PAR VALUE

---

(Title of Class of Securities)

037032-10-9

---

(CUSIP Number)

December 31, 2004

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**



13G

CUSIP No. 037032-10-9

---

1. Name of Reporting Person: I.R.S. Identification Nos. of above persons (entities only):  
Garo H. Armen

---

2. Check the Appropriate Box if a Member of a Group:

(a)

(b)

---

3. SEC Use Only:

---

4. Citizenship or Place of Organization:  
United States of America

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

5. Sole Voting Power:  
711,291 <sup>(1)</sup>

6. Shared Voting Power:  
11,489,274 <sup>(2)</sup>

7. Sole Dispositive Power:  
711,291 <sup>(1)</sup>

8. Shared Dispositive Power:  
11,489,274 <sup>(2)</sup>

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
12,200,565

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

---

11.

Percent of Class Represented by Amount in Row (9):  
26.8%

---

12. Type of Reporting Person:  
IN

---

(1) Includes 706,291 shares issuable upon exercise of options to purchase Antigenics Inc. common stock.

(2) Consists of (i) 11,154,274 shares held by Antigenics Holdings LLC, of which Dr. Armen is the Chief Executive Officer, Chairman of the Board of Managers and a member and (ii) 335,000 shares held by Armen Partners LP, of which Dr. Armen is the General Partner.

---

13G

CUSIP No. 037032-10-9

---

1. Name of Reporting Person: Antigenics Holdings LLC  
I.R.S. Identification Nos. of above persons (entities only): 13-4060592

---

2. Check the Appropriate Box if a Member of a Group:  
(a)    
(b)

---

3. SEC Use Only:

---

4. Citizenship or Place of Organization:  
United States of America

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

5. Sole Voting Power:  
11,154,274

---

6. Shared Voting Power:

---

7. Sole Dispositive Power:  
11,154,274

---

8. Shared Dispositive Power:

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
11,154,274

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

---

11. Percent of Class Represented by Amount in Row (9):  
24.5%

---

12. Type of Reporting Person:  
OO Limited Liability Company

---

---

13G

CUSIP No. 037032-10-9

---

1. Name of Reporting Person: Armen Partners LP  
I.R.S. Identification Nos. of above persons (entities only): 22-2964842

---

2. Check the Appropriate Box if a Member of a Group:  
(a)    
(b)

---

3. SEC Use Only:

---

4. Citizenship or Place of Organization:  
United States of America

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

5. Sole Voting Power:  
335,000

---

6. Shared Voting Power:

---

7. Sole Dispositive Power:  
335,000

---

8. Shared Dispositive Power:

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
335,000

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

---

11. Percent of Class Represented by Amount in Row (9):  
0.7%



---

12. Type of Reporting Person:  
PN Limited Partnership

---

---

**Item 1.**

Item 1(a) Name of issuer: Antigenics Inc.

Item 1(b) Address of issuer's principal executive offices: 630 Fifth Avenue, Ste 2100  
New York, NY 10111

**Item 2.**

2(a) Name of person filing: Garo H. Armen  
Antigenics Holdings LLC  
Armen Partners LP

2(b) Address or principal business office or, if none, residence: For each reporting person: c/o Antigenics Inc.  
630 Fifth Avenue, Ste  
2100  
New York, NY 10111

2(c) Citizenship: Garo H. Armen is a citizen of the United States of America. Antigenics Holdings LLC is a Delaware limited liability company. Armen Partners LP is a Delaware limited partnership.

2(d) Title of class of securities: Common Stock, \$0.01 par value

2(e) CUSIP No.: 037032-10-9

**Item 3.**

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- a.  Broker or dealer registered under Section 15 of the Act.
  - b.  Bank as defined in Section 3(a)(6) of the Act.
  - c.  Insurance company as defined in Section 3(a)(19) of the Act.
  - d.  Investment company registered under Section 8 of the Investment Company Act of 1940.
  - e.  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  - f.  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
  - g.  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
-

- h. o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- i. o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- j. o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Not Applicable

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- a. Amount beneficially owned: See Box 9 on cover pages
- b. Percent of class: See Box 11 on cover pages
- c. Number of shares as to which such person has:
  - i. Sole power to vote or to direct the vote: See Box 5 on cover pages
  - ii. Shared power to vote or to direct the vote: See box 6 on cover pages
  - iii. Sole power to dispose or to direct the disposition of: See Box 7 on cover pages
  - iv. Shared power to dispose or to direct the disposition of: See Box 8 on cover pages

**Item 5. Ownership of 5 Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person**

Not applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable

---

**Item 8.** Identification and Classification of Members of the Group

See Exhibit 2

**Item 9.** Notice of Dissolution of Group

Not applicable

**Item 10.** Certifications

Not applicable

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 10, 2005

/s/ Garo H. Armen  
Garo H. Armen

Antigenics Holdings LLC

By: /s/ Garo H. Armen  
Name: Garo H. Armen  
Title: Manager

Armen Partners LP

By: /s/ Garo H. Armen  
Name: Garo H. Armen  
Title: Manager

---

EXHIBIT INDEX TO SCHEDULE 13G

EXHIBIT 1

Agreement as to Joint Filing of Schedule 13G

EXHIBIT 2

List of all members of group

---

EXHIBIT 1

Each of the undersigned hereby affirms that he, she or it is individually eligible to use Schedule 13G and agrees that this Schedule 13G is filed on his, her or its behalf.

Dated: June 10, 2005

/s/ Garo H. Armen  
Garo H. Armen

Antigenics Holdings LLC

By: /s/ Garo H. Armen  
Name: Garo H. Armen  
Title: Manager

Armen Partners LP

By: /s/ Garo H. Armen  
Name: Garo H. Armen  
Title: Manager

---

EXHIBIT 2  
Members of the Group

Garo H. Armen

Antigenics Holdings LLC

Armen Partners LP